Insider Selling: Liquidia (NASDAQ:LQDA) CFO Sells $1,460,949.30 in Stock

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 20,430 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total value of $1,460,949.30. Following the sale, the chief financial officer owned 345,805 shares of the company’s stock, valued at approximately $24,728,515.55. The trade was a 5.58% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Kaseta also recently made the following trade(s):

• On Wednesday, April 15th, Michael Kaseta sold 139,390 shares of Liquidia stock. The shares were sold at an average price of $40.14, for a total transaction of $5,595,114.60.

Liquidia Stock Down 3.2%

LQDA stock opened at $75.27 on Friday. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a twelve month low of $14.04 and a twelve month high of $82.96. The company’s 50 day moving average is $67.74 and its two-hundred day moving average is $48.10. The stock has a market cap of $6.69 billion, a P/E ratio of 537.68 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. The company’s quarterly revenue was up 4187.1% compared to the same quarter last year. Research analysts expect that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Liquidia

A number of institutional investors have recently modified their holdings of LQDA. Farallon Capital Management LLC raised its position in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after purchasing an additional 4,326,876 shares during the last quarter. TCG Crossover Management LLC purchased a new position in Liquidia during the 3rd quarter worth $38,887,000. MPM Bioimpact LLC increased its stake in Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after purchasing an additional 1,200,869 shares during the period. Voloridge Investment Management LLC acquired a new position in Liquidia in the third quarter valued at $12,571,000. Finally, Bank of America Corp DE raised its holdings in shares of Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after buying an additional 360,372 shares during the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC boosted their price target on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Wells Fargo & Company raised their price objective on Liquidia from $51.00 to $62.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. BTIG Research lifted their target price on Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Jefferies Financial Group reissued a “buy” rating and issued a $60.00 target price on shares of Liquidia in a report on Monday, May 11th. Finally, HC Wainwright upped their target price on Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, June 5th. Three equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).